Corrigendum to: An allosteric inhibitor of Mycobacterium tuberculosis ArgJ: Implications to a novel combinatorial therapy (EMBO Molecular Medicine, (2018), 10, 4, 10.15252/emmm.201708038);An allosteric inhibitor of Mycobacterium tuberculosis ArgJ: Implications to a novel combinatorial therapy

EMBO Molecular Medicine

Volumn 10, Issue 4, 2018, Pages

  Mishra, Archita ^a   Mamidi, Ashalatha S ^a   Rajmani, Raju S ^a   Ray, Ananya ^a   Roy, Rajanya ^a   Surolia, Avadhesha ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

combinatorial therapy; drug repurposing; infectious disease; Mycobacterium tuberculosis; Ornithine acetyltransferase

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARGININE; CYSTEINYL LEUKOTRIENE RECEPTOR 1; ETHAMBUTOL; GLUTAMATE ACETYLTRANSFERASE; ISONIAZID; LEUKOTRIENE RECEPTOR; PRANLUKAST; RIFAMPICIN; SORAFENIB; UNCLASSIFIED DRUG; ACYLTRANSFERASE; TUBERCULOSTATIC AGENT;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BACTERIAL LOAD; BACTERIAL SURVIVAL; COMBINATION DRUG THERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; HUMAN; HUMAN CELL; INTRACELLULAR BACTERIUM; LIGAND BINDING; LUNG GRANULOMA; MACROPHAGE; MOLECULAR DYNAMICS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THERMOSTABILITY; TUBERCULOSIS; ANIMAL; COMMUNICABLE DISEASE; DRUG EFFECT; METABOLISM; MICROBIOLOGY; MOLECULAR DOCKING; PATHOGENICITY;

ACETYLTRANSFERASES; ANIMALS; ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASES; MACROPHAGES; MICE; MOLECULAR DOCKING SIMULATION; MYCOBACTERIUM TUBERCULOSIS; SIGNAL TRANSDUCTION; TUBERCULOSIS;

EID: 85042437397     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201911209     Document Type: Erratum

References (43)

1. Aguiló N, Uranga S, Marinova D, Martín C, Pardo J (2014) Bim is a crucial regulator of apoptosis induced by Mycobacterium tuberculosis. Cell Death Dis 5: e1343
2. Asano K, Nakade S, Shiomi T, Nakajima T, Suzuki Y, Fukunaga K, Oguma T, Sayama K, Fujita H, Tanigawara Y et al (2009) Impact of pharmacokinetics and pharmacogenetics on the efficacy of pranlukast in Japanese asthmatics. Respirology 14: 822–827
3. Barnes NC, Pujet JC (1997) Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax 52: 523–527
4. Behar SM, Divangahi M, Remold HG (2010) Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy? Nat Rev Microbiol 7: 845
5. Behar SM, Martin CJ, Booty MG, Nishimura T, Zhao X, Gan H-X, Divangahi M, Remold HG (2011) Apoptosis is an innate defense function of macrophages against Mycobacterium tuberculosis. Mucosal Immunol 4: 279–287
6. Boshoff HIM, Myers TG, Copp BR, McNeil MR, Wilson MA, Barry CE (2004) The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem 279: 40174–40184
7. Capodagli GC, Sedhom WG, Jackson M, Ahrendt KA, Pegan SD (2014) A noncompetitive inhibitor for Mycobacterium tuberculosis's class IIa fructose 1,6-bisphosphate aldolase. Biochemistry 53: 202–213
8. Cardamone M, Puri NK (1992) Spectrofluorimetric assessment of the surface hydrophobicity of proteins. Biochem J 282: 589–593
9. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE et al (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537–544
10. Derrick SC, Morris SL (2007) The ESAT6 protein of Mycobacterium tuberculosis induces apoptosis of macrophages by activating caspase expression. Cell Microbiol 9: 1547–1555
11. Divangahi M, Desjardins D, Nunes-Alves C, Remold HG, Behar SM (2010) Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat Immunol 11: 751–758
12. Drazen JM (1998) Leukotrienes as mediators of airway obstruction. Am J Respir Crit Care Med 158: S193–S200
13. Duan L, Gan H, Golan DE, Remold HG (2002) Critical role of mitochondrial damage in determining outcome of macrophage infection with Mycobacterium tuberculosis. J Immunol 169: 5181–5187
14. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 357: 203
15. Franzblau S (2000) A rapid, microplate-based assay for evaluating the activity of drugs against Mycobacterium leprae, employing the reduction of Alamar Blue. Lepr Rev 71: S74–S75
16. Gordhan BG (2002) Construction and phenotypic characterization of an auxotrophic mutant of Mycobacterium tuberculosis defective in L-arginine biosynthesis. Infect Immun 70: 3080–3084
17. Ichiyama T, Hasegawa M, Ueno Y, Makata H, Matsubara T, Furukawa S (2005) Cysteinyl leukotrienes induce monocyte chemoattractant protein 1 in human monocytes/macrophages. Clin Exp Allergy 35: 1214–1219
18. Ichiyama T, Hasegawa M, Hashimoto K, Matsushige T, Hirano R, Furukawa S (2009) Cysteinyl leukotrienes induce macrophage inflammatory protein-1 in human monocytes/macrophages. Int Arch Allergy Immunol 148: 147–153
19. Iyer D, Vartak SV, Mishra A, Goldsmith G, Kumar S, Srivastava M, Hegde M, Gopalakrishnan V, Glenn M, Velusamy M et al (2016) Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain. FEBS J 283: 3408–3437
20. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K (2011) The challenge of new drug discovery for tuberculosis. Nature 469: 483–490
21. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23: 3–25
22. Makarov V, Manina G, Mikusova K, Mollmann U, Ryabova O, Saint-Joanis B, Dhar N, Pasca MR, Buroni S, Lucarelli AP et al (2009) Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324: 801–804
23. Makarov V, Lechartier B, Zhang M, Neres J, van der Sar AM, Raadsen SA, Hartkoorn RC, Ryabova OB, Vocat A, Decosterd LA et al (2014) Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol Med 6: 372–383
24. Marc F, Weigel P, Legrain C, Glansdorff N, Sakanyan V (2001) An invariant threonine is involved in self-catalyzed cleavage of the precursor protein for ornithine acetyltransferase. J Biol Chem 276: 25404–25410
25. Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzales J, Derrick SC, Shi R, Kumar NP, Wei W et al (2014) Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511: 99–103
26. Mdluli K, Spigelman M (2006) Novel targets for tuberculosis drug discovery. Curr Opin Pharmacol 6: 459–467
27. Neres J, Pojer F, Molteni E, Chiarelli LR, Dhar N, Boy-Rottger S, Buroni S, Fullam E, Degiacomi G, Lucarelli AP et al (2012) Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci Transl Med 4: 150ra121
28. Niesen FH, Berglund H, Vedadi M (2007) The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc 2: 2212–2221
29. Palde PB, Bhaskar A, Pedró Rosa LE, Madoux F, Chase P, Gupta V, Spicer T, Scampavia L, Singh A, Carroll KS (2016) First-in-class inhibitors of sulfur metabolism with bactericidal activity against non-replicating M. tuberculosis. ACS Chem Biol 11: 172–184
30. Ramakrishnan L (2012) Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol 37: 26–366
31. Renaud J-P, Chung C-W, Danielson UH, Egner U, Hennig M, Hubbard RE, Nar H (2016) Biophysics in drug discovery: impact, challenges and opportunities. Nat Rev Drug Discov 15: 679–698
32. Sankaranarayanan R, Cherney MM, Garen C, Garen G, Niu C, Yuan M, James MNG (2010) The molecular structure of ornithine acetyltransferase from Mycobacterium tuberculosis bound to ornithine, a competitive inhibitor. J Mol Biol 397: 979–990
33. Sassetti CM, Boyd DH, Rubin EJ (2003) Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48: 77–84
34. Sassetti CM, Rubin EJ (2003) Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci USA 100: 12989–12994
35. Singh R, Rao V, Shakila H, Gupta R, Khera A, Dhar N, Singh A, Koul A, Singh Y, Naseema M et al (2003) Disruption of mptpB impairs the ability of Mycobacterium tuberculosis to survive in guinea pigs. Mol Microbiol 50: 751–762
36. Theron AJ, Steel HC, Tintinger GR, Gravett CM, Anderson R, Feldman C (2014) Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function. J Immunol Res 2014: 608930–16
37. Tran AT, Watson EE, Pujari V, Conroy T, Dowman LJ, Giltrap AM, Pang A, Wong WR, Linington RG, Mahapatra S et al (2017) Sansanmycin natural product analogues as potent and selective anti-mycobacterials that inhibit lipid I biosynthesis. Nat Commun 8: 14414
38. Wenthur CJ, Gentry PR, Mathews TP, Lindsley CW (2014) Drugs for allosteric sites on receptors. Annu Rev Pharmacol Toxicol 54: 165–184
39. WHO (2012) Global tuberculosis report 2012. Geneva: World Health Organization
40. Xu Y, Labedan B, Glansdorff N (2007) Surprising arginine biosynthesis: a reappraisal of the enzymology and evolution of the pathway in microorganisms. Microbiol Mol Biol Rev 71: 36–47
41. Ye X-L, Lu L-Q, Li W, Lou Q, Guo H-G, Shi Q-J (2017) Oral administration of ampelopsin protects against acute brain injury in rats following focal cerebral ischemia. Exp Ther Med 13: 1725–1734
42. Zumla A, Nahid P, Cole ST (2013) Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discovery 12: 388–404
43. Zuniga ES, Early J, Parish T (2015) The future for early-stage tuberculosis drug discovery. Future Microbiol 10: 217–229